GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL
To evaluate the safety and tolerability of GB5005 in patients with CD19-positive relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).
Trial Details
- NCT ID
- NCT06875063
- Phase
- PHASE1
- Sponsor
- The First Affiliated Hospital of Xiamen University
- Status
- RECRUITING
- Cancer Type
- Lymphoma
- Interventions
- Locations (sample)
- Xiamen, Fujian, China|24.47979,118.08187
Key Eligibility Criteria
- The candidate is able to communicate effectively with researchers and sign informed consent forms in writing;
- Age greater than or equal to 18 years old and less than or equal to 70 years old, regardless of gender; Sign informed consent form;
- Non Hodgkin lymphoma confirmed by cytology and genetics;
- Positive expression of CD19 in tumor cells confirmed by flow cytometry or pathological histology;
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lymphoma Trials on Trialify →